Skip to content
SFN info

Fabry’s disease and Small Fiber Neuropathy (SFN)

Introduction to Fabry’s disease

Fabry’s disease connection to Small Fiber Neuropathy (SFN)

Association:

Fabry’s disease is a genetic disorder that results from the buildup of a particular type of fat, known as globotriaosylceramide, in the body’s cells. This buildup can lead to a variety of symptoms, including small fiber neuropathy (SFN).

  • Mechanism: The exact mechanism of how Fabry’s disease leads to SFN is not fully understood. However, it is believed that the accumulation of globotriaosylceramide in the small nerve fibers damages these nerves, leading to SFN. The damage to these nerves can cause a variety of symptoms, including pain, tingling, and numbness.

Research Updates:

There have been several recent studies that have shed light on the connection between Fabry’s disease and SFN.

  • Genetic Testing: A study published in the journal “Neurology” in 2019 found that genetic testing can be useful in identifying patients with SFN who have Fabry’s disease. This suggests that genetic testing may be a useful tool in diagnosing Fabry’s disease in patients with SFN.

  • Biomarkers: A study published in the journal “Neurology” in 2020 found that certain biomarkers in the blood may be associated with SFN in patients with Fabry’s disease. This suggests that these biomarkers could potentially be used to monitor disease progression in patients with Fabry’s disease and SFN.

  • Treatment Response: A study published in the “Journal of Medical Genetics” in 2020 found that enzyme replacement therapy, a treatment for Fabry’s disease, can improve SFN symptoms in some patients. This suggests that treating the underlying Fabry’s disease may also help manage SFN symptoms.

Symptoms of Fabry’s disease

List of Symptoms:

Fabry’s disease, a rare genetic disorder, can manifest with a variety of symptoms. Some of these symptoms may be linked to Small Fiber Neuropathy (SFN), as Fabry’s disease often involves damage to small nerve fibers.

  • Pain: This is often the first symptom of Fabry’s disease. Patients may experience episodes of pain, particularly in the hands and feet. This pain is often associated with SFN.
  • Gastrointestinal symptoms: These can include diarrhea, nausea, and abdominal pain.
  • Hypohidrosis or Anhidrosis: Reduced or absent sweating, which can lead to heat intolerance.
  • Skin lesions: Known as angiokeratomas, these small, dark red spots often appear on the skin.
  • Hearing loss: Some patients may experience hearing problems.
  • Heart problems: Over time, Fabry’s disease can lead to heart disease, including heart enlargement and irregular heart rhythms.
  • Kidney damage: In the later stages of the disease, kidney function can be affected, potentially leading to kidney failure.
  • Eye abnormalities: Changes in the cornea and other parts of the eye can occur.

Severity:

The severity of symptoms in Fabry’s disease can vary widely from person to person, even among members of the same family. Some people may have mild symptoms, while others may experience severe complications.

  • Mild symptoms: These can include occasional pain episodes, minor gastrointestinal symptoms, and a few angiokeratomas.
  • Moderate symptoms: At this stage, patients may experience more frequent pain episodes, more significant gastrointestinal symptoms, and more widespread angiokeratomas. They may also start to have problems with heat intolerance and may notice changes in their eyes or hearing.
  • Severe symptoms: In severe cases, Fabry’s disease can lead to serious complications such as heart disease, kidney failure, and stroke. These complications can be life-threatening.

Onset:

Symptoms of Fabry’s disease typically begin in childhood or adolescence, although they can sometimes appear in adulthood.

  • Early-stage symptoms: The earliest symptoms are often episodes of pain, particularly in the hands and feet, and gastrointestinal symptoms. Reduced sweating and heat intolerance can also occur early in the disease.
  • Late-stage symptoms: As the disease progresses, more serious complications can develop. These can include heart disease, kidney damage, and stroke. Changes in the eyes and hearing loss can also occur later in the disease.## Diagnosis of Fabry’s disease

Diagnosis of Fabry’s disease

Methods:

The diagnosis of Fabry’s disease involves a combination of clinical evaluation, genetic testing, and enzyme analysis.

  • Clinical evaluation: Physicians look for characteristic signs and symptoms of Fabry’s disease, such as pain in the hands and feet, clusters of small, dark red spots on the skin (angiokeratomas), decreased sweating (hypohidrosis), cloudiness of the front part of the eye (corneal opacity), and gastrointestinal problems.

  • Enzyme analysis: The definitive diagnosis of Fabry’s disease is typically made by measuring the activity of the enzyme alpha-galactosidase A in the blood or other body tissues. Reduced activity of this enzyme suggests a diagnosis of Fabry’s disease.

  • Genetic testing: Genetic testing can be used to identify mutations in the GLA gene, which causes Fabry’s disease. This can confirm the diagnosis and can also be used for carrier testing and prenatal diagnosis.

Differential Diagnosis:

Several conditions can present with similar symptoms to Fabry’s disease and may be considered in the differential diagnosis, especially in the context of small fiber neuropathy (SFN). These include:

  • Diabetic neuropathy: This is a common cause of SFN and can cause similar symptoms to Fabry’s disease, such as pain and numbness in the extremities.

  • Amyloidosis: This condition can cause neuropathy and gastrointestinal symptoms, similar to Fabry’s disease.

  • Erythromelalgia: This is a rare condition that causes episodes of burning pain and redness in the extremities, which can be similar to the pain experienced in Fabry’s disease.

  • Other hereditary neuropathies: Other genetic conditions, such as Charcot-Marie-Tooth disease, can also cause neuropathy and may be considered in the differential diagnosis.

Limitations:

There are several challenges and limitations in diagnosing Fabry’s disease:

  • Overlap of symptoms: Many of the symptoms of Fabry’s disease, such as pain and numbness in the extremities, gastrointestinal symptoms, and kidney problems, are non-specific and can be seen in many other conditions. This can make it difficult to diagnose Fabry’s disease based on symptoms alone.

  • Variable presentation: Fabry’s disease can present with a wide range of symptoms and severity, even within the same family. This can make it difficult to recognize and diagnose the condition.

  • Lack of awareness: Fabry’s disease is a rare condition, and many physicians may not be familiar with it. This can lead to delays in diagnosis and treatment.

  • Limitations of testing: While enzyme analysis and genetic testing can confirm a diagnosis of Fabry’s disease, these tests may not be available in all settings. Additionally, not all mutations in the GLA gene have been identified, so a negative genetic test does not completely rule out the disease.

Treatments for Fabry’s disease

Options:

Fabry’s disease is a rare genetic disorder that results from the buildup of a particular type of fat, called globotriaosylceramide, in the body’s cells. It is often linked with Small Fiber Neuropathy (SFN). Here are the treatment options:

  • Enzyme Replacement Therapy (ERT): This is the standard treatment for Fabry’s disease. ERT replaces the missing or malfunctioning enzyme in patients with a synthetic version. Two types of ERT are available: Agalsidase beta (Fabrazyme) and Agalsidase alfa (Replagal).

  • Chaperone Therapy: This treatment uses small molecules to help the body’s own faulty enzyme work better. Migalastat (Galafold) is an example of this type of therapy.

  • Pain Management: Since Fabry’s disease is often associated with SFN, which can cause chronic pain, pain management is an important part of treatment. This can include over-the-counter pain relievers, prescription medications, and other non-pharmacological interventions.

Effectiveness:

  • Enzyme Replacement Therapy (ERT): ERT has been shown to help reduce pain, improve kidney function, and decrease the risk of heart problems in people with Fabry’s disease. It may also help with SFN symptoms.

  • Chaperone Therapy: Migalastat has been shown to stabilize enzyme activity and reduce the accumulation of fat in cells. It is effective in patients with amenable mutations.

  • Pain Management: The effectiveness of pain management strategies varies widely from person to person. They can be effective in managing the chronic pain associated with SFN in Fabry’s disease.

Side Effects:

  • Enzyme Replacement Therapy (ERT): Side effects can include fever, fatigue, headache, and reactions at the injection site. In rare cases, serious allergic reactions can occur.

  • Chaperone Therapy: Side effects of migalastat can include headache, nasopharyngitis, urinary tract infections, nausea, and fever.

  • Pain Management: Side effects depend on the specific medications or interventions used. They can range from constipation and drowsiness (for opioid pain relievers) to gastrointestinal issues (for NSAIDs).

Recent Advancements:

  • Gene Therapy: Researchers are exploring the use of gene therapy for Fabry’s disease. This would involve inserting a healthy copy of the gene into the patient’s cells.

  • New ERT Formulations: New formulations of ERT are being developed that may be more effective or have fewer side effects. For example, pegunigalsidase alfa (PRX-102) is a new ERT currently in clinical trials.

  • Biomarker Research: Scientists are studying new biomarkers for Fabry’s disease. These could help monitor disease progression and the effectiveness of treatments.